Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
May 14 01:27PM ET
8.40
Dollar change
+0.09
Percentage change
1.08
%
Index- P/E- EPS (ttm)-13.72 Insider Own86.04% Shs Outstand8.41M Perf Week-10.54%
Market Cap70.64M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.17M Perf Month-20.00%
Income-14.80M PEG- EPS next Q- Inst Own1.60% Short Float0.35% Perf Quarter-41.17%
Sales0.14M P/S504.61 EPS this Y- Inst Trans-3.08% Short Ratio0.64 Perf Half Y-59.91%
Book/sh5.07 P/B1.66 EPS next Y- ROA-194.70% Short Interest0.00M Perf Year-56.38%
Cash/sh0.04 P/C207.78 EPS next 5Y- ROE- 52W Range8.00 - 35.17 Perf YTD-37.96%
Dividend Est.- P/FCF- EPS past 5Y-12.67% ROI-240.23% 52W High-76.12% Beta1.11
Dividend TTM- Quick Ratio0.13 Sales past 5Y-39.80% Gross Margin-20.42% 52W Low5.00% ATR (14)1.07
Dividend Ex-Date- Current Ratio0.13 EPS Y/Y TTM-41.47% Oper. Margin-7014.08% RSI (14)38.35 Volatility6.21% 5.76%
Employees4 Debt/Eq0.80 Sales Y/Y TTM317.65% Profit Margin-10424.65% Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.13 EPS Q/Q-27.85% Payout- Rel Volume2.77 Prev Close8.31
Sales Surprise- EPS Surprise- Sales Q/Q600.00% Earnings- Avg Volume6.48K Price8.40
SMA20-15.60% SMA50-31.19% SMA200-53.70% Trades Volume11,322 Change1.08%
Serina Therapeutics, Inc. operates as a pharmaceutical company, which engages in the development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.